ClinicalTrials.gg
Not yet recruitingNCT07897708Updated Oct 30, 2026

A Study to Learn How Different Amounts of the Study Medicine Called PF-08161842 Are Tolerated and Act in the Body in Healthy and Older Adults

A Phase 1 interventional study of PF-08161842 and Placebo for PF-08161842 in Alzheimer Disease, sponsored by Pfizer. Not yet recruiting. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Updated Oct 27, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies in Alzheimer Disease by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Pfizer.

Planned enrollment
26th of 94
98 · median 56
Started
2026
the only one that year
Phase 1
52 of 101
1 open now
Registered
101st of 101
by date

Among the 101 studies in Alzheimer Disease by Pfizer, this one is the 26th largest by planned enrollment of the 94 interventional ones that give a count, is the only one that started in 2026, is one of 52 in phase 1, and was the 101st registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 101 studies in Alzheimer Disease by Pfizer is open now.

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Alzheimer Disease by Pfizer, or all of them as a file.
02

Study summary

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-08161842) and how it is processed by the body. This is the first time PF-08161842 will be given to people.

This study is seeking healthy adults:

  • 18 to 64 years of age or 65 to 85 years of age
  • Who are in generally good health
  • Who meet study conditions for body weight and body mass index (BMI)

Participants will receive either PF-08161842 tablets or matching placebo tablets. Placebo tablets do not contain active medicine. In some study groups, participants will receive a single dose of study medicine. In other study groups, they will receive the study medicine for 14 days. The tablets will be taken by mouth at the study clinic.

The investigators will compare the experiences of people receiving the study medicine with those of people who do not. This will help researchers determine if PF-08161842 is safe and how it affects the body.

Participants will stay at the study clinic for several days so the study team can closely monitor their health. The study will include physical examinations, checks of blood pressure, heart rate, temperature, and breathing. It will also include blood and urine samples and heart tracing tests (ECGs). Researchers will assess how the body processes the study medicine. Some participants will also have lumbar punctures (spinal taps) to collect small samples of fluid from around the brain and spinal cord. The study team will monitor participants for any reactions throughout the study.

For people receiving a single dose, the study will last for about 9 weeks. For those receiving multiple doses the study will last for about 11 weeks. This includes screening, study visits, clinic stay, and follow-up contact after the last dose.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • Healthy Participants
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adults, ages 18 to 64 years and healthy older adults, ages 65 to 85 years.
  2. (BMI) of 16-32 kg/m2; and a total body weight >50kg (110 lb.).

Exclusion criteria

Exclusion criteria:

  1. Evidence or history of medical conditions.
  2. Participation in studies of other products (drug or vaccine) at any time during their participation in this study.
  3. A positive urine drug test.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
98 participants (estimated)

Study arms

  • Experimental
    Part A: Cohorts 1-6 and 7 (optional)

    Participants will receive PF-08161842 or matching placebo as a single dose on Day 1.

    Drug: PF-08161842 · Drug: Placebo for PF-08161842

  • Experimental
    Part B: Cohort 8-12 and 13 (Optional)

    Participants will receive doses of PF-08161842 or matching placebo from Day 1 through Day 14.

    Drug: PF-08161842 · Drug: Placebo for PF-08161842

Interventions

  • DrugPF-08161842

    Oral tablet (Parts A and B).

  • DrugPlacebo for PF-08161842

    Matching placebo tablet (Parts A and B).

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame: From first dose through approximately 28 to 35 days after the last dose

  2. Number of Participants With Serious Adverse Events (SAEs)

    Time frame: From first dose through approximately 28 to 35 days after the last dose

  3. Number of Participants With Clinically Significant Laboratory Abnormalities

    Time frame: From first dose through approximately 28 to 35 days after the last dose

  4. Number of Participants With Clinically Significant Vital Signs Abnormalities

    Time frame: From first dose through approximately 28 to 35 days after the last dose

  5. Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings

    Time frame: From first dose through approximately 28 to 35 days after the last dose

  6. Number of Participants With Clinically Significant Columbia-Suicidality Severity Rating Scale (C-SSRS)

    Time frame: From first dose through approximately 28 to 35 days after the last dose

Secondary outcomes

  1. Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast)

    Time frame: Part A only: Up to Day 5

  2. Area Under the Curve From Time Zero to end of Dosing Interval (AUCtau)

    Time frame: Part B only: Up to Day 17

  3. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Part A: Up to Day 5 Part B: Up to Day 17

  4. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: Part A: Up to Day 5 Part B: Up to Day 17

  5. Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) if data permit

    Time frame: Part A only: Up to Day 5

  6. Plasma Decay Half-life (t1/2) if data permit

    Time frame: Part A only: Up to Day 5

  7. Cerebrospinal Fluid (CSF) Concentration of PF-08161842

    Time frame: Part A: At day 2 post dose Part B: At day 15 post dose

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 4 months is below that.

Counting every sponsor, half of 234 studies reached it within 17 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2026
First posted
Oct 27, 2026
StartEst.
Nov 17, 2026
Primary completionEst.
Mar 17, 2027
CompletionEst.
Dec 14, 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 27, 2026
Show all 2 updates
  1. Oct 30, 2026
    Minor edits only
    + 1 other change: description
  2. Oct 27, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07897708
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 27, 2026
Start date
Nov 17, 2026 (estimated)
Primary completion
Mar 17, 2027 (estimated)
Completion
Dec 14, 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion